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 Hepatitis C virus (HCV) is a major global public health problem. The Center for 
Disease Control and Prevention (CDC) estimates that the Hepatitis C virus (HCV) affects 
3.2 million Americans and 500 million people from a global standpoint (CDC, 2012). 
HCV contributes to significant morbidity and mortality with about 1 million deaths due 
to liver disease (World Hepatitis Alliance, 2010). Chronic liver disease has origins 
ranging from acquired, infectious, toxic and metabolic causes. Long-term consequences 
include cancer, cirrhosis (scarring of the liver), and liver failure. Given the substantial 
morbidity attributable to HCV-related liver disease, it is necessary to develop an HCV-
related public health plan for the prevention of new HCV infections. The source of HCV 
infection includes transfusion of blood or blood products from unscreened donors, 
exposure to blood through the use of contaminated and inadequately sterilized 
instruments and needles used in medical and holistic medicine, persons who participate in 
high-risk sexual practices, or sexual interactions with HCV-infected persons. The relative 
contribution of these various sources of infection has not yet been defined with 
population-based epidemiological studies. New infections continue to occur and burden 
global public health systems.  
The aim of this paper is to discuss the prevalence, incidence and burdens of 
chronic hepatitis C and to report on the fieldwork project completed at the California 
Pacific Medical Center in conjunction with the San Francisco Center for Liver Disease. 
Utilizing an ecological framework the role of public health to develop awareness 
opportunities about HCV, help patients access and evaluate their treatment options, and 
provide support to those newly diagnosed and their families will be examined. 
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Public Heath Problem 
 The hepatitis C virus (HCV) is recognized as a major cause of chronic liver 
disease worldwide. Moreover, hepatitis C leads to cirrhosis, which is the most common 
cause of chronic liver disease in the United States (Mueller et al., 2009). The World 
Health Organization (WHO, 1998) estimates that the prevalence of HCV infection is 2%, 
which represents 123 million people worldwide. Additionally, a liver transplant is a 
common treatment option for those with chronic liver failure to enhance the quality of 
life (WHO, 1998). The CDC predicts that the availability of highly effective antiviral 
therapies will significantly reduce the incidence rates to make HCV a rare disease by 
2036. Despite those positive trends in treatment options, 10-16% still develop cirrhosis 
(Robert et al., 2004). However, the public health problem at hand is the lack of data and 
interventions for high-risk groups such as those co-infected with HIV/AIDS (Proeschold-
Bell, 2011).  An estimated 1 million people in the United States are diagnosed with both 
HIV and HCV with approximately 56,000 new HIV infections occurring each year 
(Proeschold-Bell, 2011). 
 Accurate epidemiological data is the foundation to prevent and control any 
infection. Co-morbidities are common especially when diseases share the similar routes 
of transmission. Such is the case of HCV and HIV. Modes of transmissions are via blood 
and bodily fluids and transmission can occur via multiple portals. Risk of transmission 
exists in occupational and perinatal settings, as well as through sexual encounters, 
regardless of population or geographic region. One of the cofactors known to accelerate 
the progression of HCV among those infected is HIV (Chiao, 2014) (See Appendix A). 
The epidemiology of this cofactor is an important area of public health research and 
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education. Nevertheless, the HCV-infection population has grown so large, it is now 
considered a global endemic, even though it occurs in only a fraction of people.  
Social Ecological Model 
 Education and treatment interventions have been shown to positively influence 
behaviors related to chronic disease prevention (Wilson et al., 2006). When treatment 
options are publicly demonstrated, those more at-risk are given a reason to get tested. 
Public health interventions can be approached using the comprehensive multilevel Social 
Ecological Model (SEM). This promising approach is important for those diagnosed with 
HCV because HCV prevention and treatment occurs within multiple levels of the health 
care system. The SEM is described using five levels that influence health: 
1. Intrapersonal-beliefs and characteristics, 
2. Interpersonal-relationships and social networks such as spouse, 
friends and family 
3. Community-experiences and resources, 
4. Institutional-rules and regulations concerning healthcare, 
5. Policy-structures and environments that impact health. 
 In general, the SEM suggests that individual behavior and social environments are 
related.  This model would be beneficial in gaining more insight to target the specific 
population of those HCV-infected or at-risk for HIV. Although each level is unique, each 
level is capable of impacting one another.  Individuals infected with either HCV or both 
HIV-HCV can live a long time with their diseases and their care can impact their family 
and other relationships, as well as their community establishments, such as liver clinics 
and hospitals. Furthermore, the SEM is extremely useful in tailoring a community-based 
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intervention to a particular socio-cultural context for people with HIV and HCV that also 
includes individual intervention levels (Proeschold-Bell, 2011). For example, many feel 
hesitant to discuss their disease status because of cultural factors that fall into place. 
 Proeschold-Bell et al. (2011) utilized the social ecological model and conducted a 
multilevel intervention to improve the knowledge of HCV risk, knowledge of one's own 
HCV status, and receipt of HCV education from a medical provider of those infected 
with HIV. Their primary target group was people with HIV who already had HCV co-
infection or were at risk for HCV. The intervention was conducted at four levels of the 
SEM: intrapersonal, interpersonal, community, and institutional. At the individual level, 
participants were assigned case management and provided mental health and substance 
use counseling and included harm reduction such as reduced and clean needle use. At the 
interpersonal level, monthly support groups were offered at 2 sites. At the community 
level, health classes were offered to the general public as well as HIV infected persons 
who were at risk for HCV infection. A public media campaign was also launched to 
inform and educate people about HCV risk, transmission and treatment.  At the 
institutional level, information technology was changed at HIV clinics that enabled the 
creation of a face sheet to be placed on the charts to flag if a patient was tested for HCV, 
the test date and results, and whether or not the patient was vaccinated against hepatitis A 
or B.  In addition medical providers were educated on HIV-HCV co-infection patient 
care, HCV treatment, testing, and transmission.   
 The sample included n = 259 participants of whom data were collected every two 
weeks over a two year period.  This Interrupted Time Series design enabled the 
researchers to collect pre intervention community data and continue throughout the 
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intervention period over time.  Demographics of the participants included: mean age of 
43 years old; 68.3% male; 58.3% African-American; 76% with high school education; 
and 24%with a college degree or higher. Patient characteristics were tested systemically 
as “covariates” so that only statistically significant covariates were kept in the final 
analysis. Data collection methods included face-to-face interviews, which included 
questioning participants about their HIV status, whether they knew about HCV risk 
behaviors, and history of high-risk sexual encounters. Participants were also asked 
whether or not they had been tested for HCV and if they received education on HCV 
from their respective provider(s) (Proeschold-Bell et al., 2011).  
 Results demonstrated that “accurate HCV knowledge among patients with HIV 
was higher during the intervention phase than the pre-intervention phase” (p. 8). (See 
Appendix B for complete results.) The authors reported that the framework of SEM was a 
successful guide and the primary goal was achieved. The HIV-positive population is 
increasing in liver-related mortality, which makes HCV prevention and treatment a 
significant priority. 
HCV prevention can be addressed on multiple levels represented in the social 
ecological model and on all levels of prevention—primary, secondary, and tertiary.  Liver 
transplants would be considered a tertiary prevention that entails interventions on 
multiple levels of the SEM such as intrapersonal (the need for individuals to maintain a 
healthy lifestyle and resist alcohol and drug consumption), interpersonal (working with 
clear communication between discordant couples to reduce transmission, as well as 
drumming up social support for liver transplant candidates), and organizational levels 
such as transplant organizations to assure the effective and thorough care and selection of 
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transplant candidates to guarantee success and efficient use of limited public resources.  
Work done in this fieldwork placement was mostly focused on the organizational level of 
a transplant center although intrapersonal education and care as well as interpersonal 
support was included in the center's scope of practice.   
Fieldwork Details 
 Due to the high volume of patients consistently being diagnosed with various liver 
diseases, the primary goal of this fieldwork project conducted at the California Pacific 
Medical Center in conjunction with the San Francisco Center for Liver Disease was to 
promote and facilitate communication among the team and develop better guidelines for 
patient care. This fieldwork experience focused on providing a highly specialized 
framework to outpatient registered nurses. The role of the Transplant Specialist was 
further developed to enable integration between all team members of the liver and heart 
transplant department. In the first 30 days, it was essential to monitor and track the 
number of phone calls in order to provide significant patient data of incoming calls. 
These calls were due to the elevated number of patients in the hepatology and transplant 
program(s). The nurses were not able to provide sufficient care due to the high volume. 
Therefore, this fieldwork experience not only provided primary support to the nurses but 
also reduced their workload to prevent medical errors while practicing medicine.  
 All goals were accomplished through activities guided by detailed objectives. 
These objectives were organized meticulously as the fieldwork progressed. The first 
objective was in correlation with goal one.  In order to become familiar with the general 
service of this clinic and hospital, it was vital to complete an extensive assessment of 
department materials during orientation. This involved arranging several meetings with 
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multiple members of the hepatology and transplant department to better understand each 
specific individual role. Furthermore, it was necessary to attend and participate in all 
department meetings. Observing how each team member worked together helped 
understand how patients are commonly organized towards the end result: a healthy 
quality of life.   
 The final learning objective was to implement clinic-based projects aimed at a 
non-clinical level. These projects included data collection for compliance with United 
Network for Organ Sharing (UNOS), transition patients who are  >5 years post-transplant 
to primary care and the development of the prior authorization packet for hepatitis C 
treatment medications. It was essential to understand how compliance and ethical 
considerations were formulated within the hospital policies and procedures; every 
protocol is interwoven between numerous pathways. Principally, the hospital and clinic 
change their protocols every so often due to federal regulations such as Centers for 
Medicaid Services (CMS), United Network for Organ Sharing (UNOS) and Donor 
Network West (California’s Organ Procurement Center). Consistently changing protocols 
aids to explore risk-benefits as well as ensure safer practices for patients. These 
preventive measures are based upon a national data derived from individual and 
population-level statistics. The fieldwork project simplified strategies to establish, 
enhance and developed the initial role of the Transplant Specialist as an important asset 
in the public health prevention segment. (See Appendix B for SMART goals.) 
 
 
 
Running head: HCV THROUGH THE ECOLOGICAL MODEL  10 
Public Health Significance 
 California Pacific Medical Center Department of Liver Transplant is a united 
multidisciplinary community consisting of surgeons, transplant hepatologists, social 
workers, financial analysts, nutritionists and nurses. This team is “designed” to 
encompass all to fundamentally provide the best care and support for all patients’ part of 
the program. Each patient in the program starts in the hepatology “phase.” This means 
that any patient a part of the hepatology phase is battling a specific liver disease. For 
example, hepatitis B, autoimmune hepatitis and hepatitis C are of the most common. If 
the patient’s primary hepatologist believes that a patient is “ready” to be evaluated for a 
transplant, then the patient is moved into the “evaluation” phase. During evaluation, 
patients undergo a series of diagnostic tests, lab work and a mandatory psychosocial 
assessment. Additionally, it is a requirement for the patient to have a valid support 
person. The support person is also evaluated by a licensed social worker if she or he can 
withstand the necessary and complex care for a recently transplanted person. Once a 
patient is listed, the patient is placed in the donor “pool” based on MELD score and blood 
type. MELD score is defined as: “Model for End Stage Liver Disease.” The MELD score 
ranges from 6-40; patients are arranged into either low-MELD (6-20) or high-MELD (21-
40). Sometimes patients get deactivated because their liver disease has improved even 
though they may still be symptomatic.  
 While the program is highly organized, the public health problem(s) presented 
needs continuous time and effort to develop interventions that would be more successful 
and efficient.  Recently, a successful cure for HCV has been developed. An abundance of 
hepatitis C medication orders began to occur in late 2014 when the Federal Drug 
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Administration approved the hepatitis C treatment drug, Harvoni. Harvoni is the first 
combination pill approved to treat chronic HCV genotype 1 infection (FDA, 2014). It is 
also the first approved regimen that does not require administration with interferon or 
ribavirin, two FDA-approved drugs also used to treat HCV infection (FDA, 2014). The 
efficacy of Harvoni was evaluated and observed in multiple clinical trials involving 
patients that were either treatment-naïve or treatment-experienced (Gilead Sciences, 
2015). These trials were designed to measure whether or not the virus was detected in the 
blood after 12 weeks of treatment. This is known as a “sustained viral response” (SVR). 
Due to the miraculous discovery that the medication, Harvoni significantly reduced the 
detection of the virus (SVR), the clinic experienced a significantly high increase in the 
amount of medications ordered. It is an understatement to note that patients chronically 
diagnosed with hepatitis C for over two decades were interested in this revolutionary 
medication. Hence, a protocol was implemented to stay as organized as possible. This 
protocol added the duty of the Transplant Specialist to respond to these orders in a timely 
fashion. The role of the Transplant Specialist expedited HCV orders while adhering to an 
established protocol. Although the epidemiological data are limited, other agents awaiting 
FDA approval are expanding as part of the advancing public health surveillance and 
development of effective treatments to combat HCV.  
Conclusion 
 It is difficult to prevent and control chronic liver disease due to the multiple 
contributing factors. Regrettably, there is no vaccine and no post-exposure prophylaxis for 
HCV. Many also do not seek care because they don't know they are infected; the incubation 
period for HCV can be decades long (Kamal, 2008). Primary prevention tactics should 
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include but not be limited to: safer blood transfusions in developing countries, and safer 
injection practices in health care and in other settings such as tattoo parlors. Individuals 
who are HIV-infected and inject drugs may find it difficult to retain knowledge about HCV 
transmission. Data suggest that injecting drug use between intimate partners is a significant 
contribution to the occurrence of the hepatitis C infection mostly because those with HCV 
who are in intimate relationships often do not disclose their status to their partners (Seear et 
al., 2012).  Furthermore, unprotected sexual relations between discordant couples increases 
transmission rates even more (Seer et al., 2012). The public health community must 
address this risk in order to reduce the transmission of HCV. 
 The need to coordinate efforts for either primary HCV prevention focused on 
a specific risk-group or secondary prevention efforts such as the ability of those 
infected with HCV to receive effective treatment drugs without delay are both 
crucial public health imperatives. Future prevention efforts should include the 
development of educational materials that can be posted in a clinic or within the 
community to encourage patients to attend classes, get tested and practice safer sex, 
especially in those already receiving counseling with HIV. Training HIV providers early 
about HCV infection may also be implemented during appointments, as some may never 
have had formal medical training on hepatitis in general. Lastly, it may also be wise to 
initiate a system-wide electronic medical record for those who pose significant risk when 
visiting healthcare providers, or being admitted into hospitals. These strategies can help 
minimize incidence of new cases and thus decrease the overall prevalence of HCV. 
Reducing incidence of HCV would greatly decrease the need for liver transplants in those 
with chronic liver damage and thus save valuable resources that could be utilized for 
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primary prevention.  These recommendations are consistent from the CDC’s HCV 
National Prevention Strategy for Health Professionals (CDC, 2010). 
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Appendix A 
 
HCV Progression of Disease 
 
 
 
 
 
Source: Chiao, H., & Frenette, C. (2014). Solid Organ Transplantation: Little Research, Big 
Need for Patients with HCV
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Appendix B 
 
Social Ecological Model 
 
Level  
of influence 
Definition Example 
Intrapersonal • Individual behaviors • Substance abuse 
counseling 
• HCV antiviral therapy 
• Sexual abstinence 
Interpersonal • Family 
• Friends 
• Co-workers 
• Neighbors 
• Support groups for those in 
close relationships with 
infected populations 
Organizational Community • Neighborhoods 
• Churches 
• County jails 
• Media 
• Homeless shelters 
• Free health classes to the 
available general public 
• Training HIV educators on 
HCV 
• Public health campaigns 
such as websites that offers 
locations of free test sites 
Public Policy* • Laws  - both local, 
state and federal 
• More public awareness 
• Free testing sites  
• Government assistance 
programs for cost-effective 
treatment  
 
 
Source:  Proeschold-Bell, R.,Hoeppner,B., Taylor,B., Cohen,S., Blouin, R., Stringfield,B, 
& Muir, A. (2011). An interrupted time series evaluation of a hepatitis c intervention for 
persons with HIV. AIDS Behaviors, 15(8), 1721-1731 
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Appendix C continued 
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Appendix C continued 
 
SMART Goals 
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Competencies Addressed 
 
 Multiple competencies part of USF’s MPH Program was addressed throughout 
this fieldwork experience: 
1. Assess, monitor, and review the health status of populations and 
their related determinants of health and illness 
2. Identify and prioritize the key dimensions of a public health 
problem by critically assessing public health literature utilizing 
both quantitative and qualitative sources. 
3. Develop public health programs and strategies responsive to the 
diverse cultural values and traditions of the communities being 
4. Identify and apply ethical, moral, and legal principles in all 
aspects of public health practice. 
 Competency #1 was continuously observed; reviewing data related to patients 
diagnosed with chronic liver disease as well as the social determinants discussed during 
the transplant evaluation phase of the hepatology program. Observing determinants such 
as, a history of drug and alcohol use was vital towards understanding the population at 
hand. Furthermore, competency #2 was achieved because of the management of 
quantitative and qualitative data consistently being investigated with UNOS compliance. 
Reviewing patients’ charts for compliance was broadly towards successful validation of 
the UNOS forms. Moreover, patients in process of starting HCV treatment are required 
compliance; maintaining all blood work and diagnostic imaging tests.  
 Developing public health programs and strategies based on diverse cultural values 
was a unique yet critical competency. For patient’s diagnosed with HCV, the treatment 
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plan was based specifically on genotype (See Appendix B). Genotype bases the 
physician’s care plan because of the patient’s geographical origin. This competency was 
achieved through orders directed from the providers; it was clear that genetics make it 
critical regarding the “design” of treatment. Lastly, competency #4 was analytical in the 
development of protocol(s). Emerging liver diseases involves professionals to ask, “What 
is the right thing to say or do? Ethical values have always provided a foundation for the 
public health practice. The Transplant Specialist role delivered ethnical questioning, yet 
positively expanded the relationship(s) between patients and the clinic. Developing this 
role was crucial because of patient volume and the need to improve patient care was 
obvious. Conceptualizing public health within the field of clinical medicine will involve 
challenges along the way, but the prevention of disease, promotion of health and 
development of policy will increase in scope and sophistication (Slomka et al, 2008). 
Reflection 
 
 To conclude, this fieldwork experience was an excellent professional learning 
experience. California Pacific Medical Center, in conjunction with the San Francisco 
Center for Liver Disease provide a sufficient environment that is supportive, innovating 
and challenging in the intricate world of healthcare. Meetings, presentations, series 
lecture, conferences and personal one-on-one interviews expanded my knowledge 
heavily. The two preceptors have exceeded all my expectations through example: 
coaching, training, and providing detailed answers to answers. As an MPH candidate, I 
was able to witness first hand cases with these two preceptors or registered nurses. This 
experience was far more interesting because I witnessed a management side and a clinical 
Running head: HCV THROUGH THE ECOLOGICAL MODEL  25 
nursing side. Further, I was able to utilize my leadership skills by training other members 
of the team with my past experience as a pharmacy technician.  
 Although the majority of my role was to establish a HCV protocol, it was truly 
eye opening to witness a regular person get diagnosed with chronic end stage liver 
disease, go through the process of being listed for a new organ and then suddenly, get 
transplanted as if the disease never occurred. It is a miraculous how far medicine and 
technology improved the last decade and as a MPH, I intend to be a part of this revolution 
as CPMC’s opens new hospital doors in 2020. I intend to promote HCV awareness, 
advocacy for organ donation while utilizing the skills I’ve achieved in my epidemiology, 
advanced biostatistics, communication for healthy communication, social justice and 
policy and this fieldwork experience. My skills will continue to improve and as a 
Transplant Specialist, I believe that improving patient lives is by far the most important.
 
